A carregar...
Oral Administration of a Specific Kynurenic Acid Synthesis (KAT II) Inhibitor Attenuates Evoked Glutamate Release in Rat Prefrontal Cortex
Cognitive deficits represent core symptoms in schizophrenia (SZ) and predict patient outcome; however, they remain poorly treated by current antipsychotic drugs. Elevated levels of the endogenous alpha7 nicotinic receptor negative allosteric modulator and NMDA receptor antagonist, kynurenic acid (KY...
Na minha lista:
| Publicado no: | Neuropharmacology |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5803791/ https://ncbi.nlm.nih.gov/pubmed/28419874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2017.04.023 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|